Cizzle Biotechnology Holdings PLC Total Voting Rights (5834E)
2023年7月1日 - 1:00AM
RNSを含む英国規制内ニュース (英語)
TIDMCIZ
RNS Number : 5834E
Cizzle Biotechnology Holdings PLC
30 June 2023
30 June 2023
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Total Voting Rights
Cizzle Biotechnology, the UK based diagnostics developer, makes
the following announcement in accordance with Rule 5.6.1 of the
Financial Conduct Authority's ("FCA") Disclosure Guidance and
Transparency Rules.
As of 30 June 2023, the Company's issued ordinary share capital
consists of 363,841,773 ordinary shares of 0.01 pence each, each
with one voting right. The Company holds no ordinary shares in
Treasury. Therefore, the Company's total number of ordinary shares
and voting rights is 363,841,773 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Enquiries:
Cizzle Biotechnology Holdings Via IFC Advisory
plc
Allan Syms (Executive Chairman)
Allenby Capital Limited +44(0) 20 33285656
John Depasquale
George Payne
Novum Securities Limited +44(0) 20 7399 9400
Colin Rowbury
Jon Bellis
IFC Advisory Limited +44(0) 20 3934 6630
Tim Metcalfe cizzle@investor-focus.co.uk
Florence Chandler
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early
detection of lung cancer. Cizzle Biotechnology is a spin- out from
the University of York, founded in 2006 around the work of
Professor Coverley and colleagues. Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a
variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell
nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early-stage lung cancer.
For more information, please see
https://cizzlebiotechnology.com
You can also follow the Company through its twitter account
@CizzlePlc and on LinkedIn.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREAFKEDAFDEFA
(END) Dow Jones Newswires
June 30, 2023 12:00 ET (16:00 GMT)
Cizzle Biotechnology (LSE:CIZ)
過去 株価チャート
から 5 2024 まで 6 2024
Cizzle Biotechnology (LSE:CIZ)
過去 株価チャート
から 6 2023 まで 6 2024